HARTREE-PARTNERS
7.3.2024 08:01:28 CET | Business Wire | Press release
Hartree Partners (UK) Limited (“Hartree”), a wholly owned subsidiary of Hartree Partners LP, which is co-owned by its partners and funds managed by Oaktree Capital Management, announced that it has signed an acquisition agreement for a 50% share in Botres Holding GmbH and its subsidiaries (“Botres”). Headquartered in Graz, Austria, Botres is a key supplier of ultra-modern industrial biogas plants and biorefineries in Austria, Czech Republic, Poland, Italy, Spain and Turkey. Through Bio Scraper, its highly efficient biowaste treatment system, Botres covers the entire processing chain from pre-treatment of all types of organic waste to the efficient production of green energy.
Since being founded in 2012, Botres has built numerous biogas plants across Europe and Turkey and serves some of the world’s largest waste management and infrastructure companies. Botres is led by its founders Dr. Stefan Kromus and Dr. Markus Grasmug, who serve as Managing Directors. Jointly, Dr. Kromus and Dr. Grasmug have over 40 years of experience in the design, development, construction, and operation of waste focused biomethane plants.
Hartree is partnering with Botres to develop a European biomethane production business with a focus on Renewable Energy Directive (RED) compliant feedstocks, which will operate under the Botres brand. The business will focus asset development activities in select countries within the EU and will expand into additional countries on an opportunity-led basis.
“We are excited to partner with Botres, whose innovative technology and proven track record in the biogas space make them an excellent partner for our team as we enter the European biomethane production market. This collaboration directly aligns with Hartree's transition to investing in renewable energy solutions and we look forward to playing a role in providing Europe with clean and reliable biomethane,” said Stephen Hendel, Founding Managing Partner of Hartree Partners LP.
Dr. Kromus said, “We are thrilled to embark on this new chapter with Hartree Partners. This partnership presents a significant opportunity to accelerate the growth of our biomethane production business and solidify Botres' position as a leading player in the industry. We are confident that by combining our expertise and resources, we can deliver exceptional results for our stakeholders and contribute meaningfully to Europe's transition towards a more sustainable energy future.”
About Hartree:
Hartree Partners (UK) Limited is a wholly owned subsidiary of Hartree Partners, LP a limited partnership organised under the laws of Delaware and is a global commodities firm actively trading in oil, gas, power, refined products, shipping, metals and equities. Hartree Partners, LP was established more than 25 years ago and is jointly owned by senior management and funds managed by Oaktree.
Hartree has a unique 25+ year track record in proprietary trading and investing in energy markets across the globe. Our asset development experience ranges from VLCCs, oil, gas and power storage, power generation (conventional & renewable), and gas production facilities, as well as oil refining assets in the US. In Europe Hartree is involved in the UK power market through a portfolio of peak power assets, as well as a portfolio of pan-European renewable generation assets. Hartree acquired a deep knowledge base in the operation of these assets through extensive data analytics and has a wealth of experience in structuring transactions for renewable power and managing intermittent load.
About Botres:
Botres Holding/Botres Global GmbH, headquartered in Graz, Austria, is a leading supplier of modern industrial-scale anaerobic digestion biogas technology, covering the entire process chain from pre-treatment of all types of organic waste, manure and other residues to the efficient production of green energy. Botres was founded in 2012 and emerged from technology development at one of the world’s largest and most successful anaerobic digestion plants in Italy.
Over the past years, Botres has built numerous biogas plants in various European countries, Turkey and Australia. Among Botres’ customers are some of the largest waste management and infrastructure companies in the world. With the development of its highly efficient biowaste treatment system (Bio Scraper), Botres is able to treat basically any type of organic waste. In addition, the technological design and process stability of the plants ensure optimized life cycle expenditures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240306806400/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angel Aligner Unveils Six Innovations for 202711.11.2026 17:23:00 CET | Press release
Angel Elevates the Orthodontic Specialty by Focusing on Complex-Case Solutions Angelalign Technology Inc. (6699.HK) (“Angel”), a global clear aligner leader, has unveiled six new clinical innovations, including SuperElastic (MC-SE)* aligner material, a Deepbite Solution for significantly expanded indications, and the Adapt-MATMsystem for next generation growth guidance for young patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110338654/en/ Unveiling Angel's 2027 Innovations. Orthodontists and opinion leaders have long remarked about Angel’s clinical excellence. Orthodontics educator and thought leader Dr. David Sarver said: “In over 4 decades, I’ve never had a parent say I’d be happy if you ensure that my child’s treatment results are average.” Angel is committed to elevating the orthodontic specialty well above the average, especially as more competition and harder referral cases demand outstanding results. Bind
Abu Dhabi Future Health Summit Concludes with Research Partnerships and New Programmes to Advance Prevention and Health Innovation11.11.2026 15:58:00 CET | Press release
Partnerships span drug discovery, clinical research, preventive and reproductive health Launch of an AI Clinician Framework and a Trusted Research Environment for health and genomic data Four whitepapers address genomics, therapeutics, fertility and wearable technologies New programmes support health innovators and entrepreneurs More than 17,300 visitors from 85 countries, with 130 speakers across 45 sessions Held under the patronage of His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, Abu Dhabi Future Health Summit 2026 concluded with agreements and initiatives spanning drug discovery, clinical research, preventive and reproductive health, alongside research and entrepreneurship programmes that will sustain collaboration beyond the Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261111545964/en/ The Summit is the annual flagship gath
De' Longhi Group: Record Results for the Quarter, With Revenue Growing by 7.7% and Net Profit Pertaining to the Group Progressing Significantly by 19%11.11.2026 15:58:00 CET | Press release
The Board of Directors of De' Longhi S.p.A. approved the consolidated results1 for the nine months of 2026. In the nine months the Group achieved: revenues for € 2,621.3 million, up by 6.5% with respect to 2025 (+7.7% at constant currency); an adjusted2 Ebitda of € 455.2 million, equal to 17.4% on revenues (vs. 15.8% with respect to last year); a net income pertaining to the Group equal to € 225.8 million (+20.4% with respect to last year); a positive net financial position equal to € 606.0 million. CEO Fabio de' Longhi commented: “The Group delivered its thirteenth consecutive quarter of organic revenue growth, underscoring our proven ability to capitalize on industry opportunities and respond promptly to market evolution, while ensuring consistent performance across both divisions. The professional business recorded a strong acceleration, spanning all geographies and brands, with revenues growth exceeding 35% for both the quarter and the nine-month period, this against an already par
Starr Chile Assigned A Rating from AM Best11.11.2026 14:30:00 CET | Press release
Starr, a global insurance and investment organization, today announced that the global credit rating agency AM Best has assigned Starr International Seguros Generales S.A. (Starr Chile) a Financial Strength Rating of A (Excellent) and a Long-Term Issuer Credit Rating of a+ (Excellent). The outlook for both credit ratings is positive. The rating reflects Starr’s strong balance sheet and Starr Chile’s successful implementation of Starr’s business model. AM Best also cited Starr’s operating performance, a favorable business profile and enterprise risk management as key factors supporting the positive rating. “This strong rating is another important endorsement of Starr’s business model as we continue to build our presence in Latin America,” said Jeff Greenberg, chairman and co-CEO of Starr. “It reflects the financial strength, underwriting discipline and experienced teams that underpin our business around the world, reinforcing the confidence brokers and clients can place in Starr.” Starr
Epinal, Inc. Emerges from Stealth with First-of-Its-Kind Breakthrough Semiconductor Electrochemical Biosensor (SEB) for Detection of Narcotics and Disease Biomarkers in Human Breath in Minutes11.11.2026 14:22:00 CET | Press release
Southern California-Based Company has developed a disruptive biosensor for integration into next-generation screening and diagnostic devices Epinal, Inc., after over six years of under-the-radar development, has officially emerged from stealth mode, introducing a breakthrough Semiconductor Electrochemical Biosensor (SEB) designed to detect narcotics and disease biomarkers directly from human breath in minutes. By combining advanced semiconductors, electrochemical sensing, tailored protein engineering, and artificial intelligence, Epinal has addressed the historical sensitivity, selectivity, scaling, stability, and signal-to-noise limitations that have long bottlenecked biosensors. Epinal’s Semiconductor Electrochemical Biosensor (SEB) will be integrated into the next generation of low cost, disposable, single-use breathalyzer cartridges where the integrity of test results is of utmost importance. In the case of narcotic detection, a rapid, non-invasive, and objective result changes an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom